Pulmatrix logo

PulmatrixNASDAQ: PULM

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

21 March 2014

Next earnings report:

08 November 2024

Last dividends:

N/A

Next dividends:

N/A
$7.89 M
-84%vs. 3y high
16%vs. sector
-vs. 3y high
-vs. sector
-47%vs. 3y high
32%vs. sector
-90%vs. 3y high
18%vs. sector

Price

after hours | Fri, 01 Nov 2024 22:43:10 GMT
$2.16-$0.04(-1.82%)

Dividend

No data over the past 3 years
$1.55 M-$5.81 M

Analysts recommendations

Institutional Ownership

PULM Latest News

Pulmatrix Announces Second Quarter 2024 Financial Results and Provides Corporate Update
prnewswire.com13 August 2024 Sentiment: POSITIVE

Completed series of transactions with MannKind Corporation validating iSPERSE ™ technology and extending projected cash runway into Q4 2026 $12.4 million in cash and cash equivalents at the end of Q2 2024, with an additional $1.4 million in restricted cash becoming unrestricted in August 2024 Pursuing strategic alternatives to further leverage iSPERSE ™ and optimize the potential of PUR3100 FRAMINGHAM, Mass. , Aug. 13, 2024 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (Nasdaq: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious central nervous system and pulmonary disease using its patented dry powder inhalation iSPERSE™ technology, today announced second quarter financial results for 2024 and provided a corporate update on its clinical assets.

Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation
prnewswire.com29 May 2024 Sentiment: POSITIVE

Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket® inhalation device. Pulmatrix transferring leased building, all leasehold improvements, laboratory equipment and other related personal property in exchange for MannKind assumption of lease.

What type of business is Pulmatrix?

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

What sector is Pulmatrix in?

Pulmatrix is in the Healthcare sector

What industry is Pulmatrix in?

Pulmatrix is in the Biotechnology industry

What country is Pulmatrix from?

Pulmatrix is headquartered in United States

When did Pulmatrix go public?

Pulmatrix initial public offering (IPO) was on 21 March 2014

What is Pulmatrix website?

https://www.pulmatrix.com

Is Pulmatrix in the S&P 500?

No, Pulmatrix is not included in the S&P 500 index

Is Pulmatrix in the NASDAQ 100?

No, Pulmatrix is not included in the NASDAQ 100 index

Is Pulmatrix in the Dow Jones?

No, Pulmatrix is not included in the Dow Jones index

When was Pulmatrix the previous earnings report?

No data

When does Pulmatrix earnings report?

The next expected earnings date for Pulmatrix is 08 November 2024